Chronic hypnotic use: Deadly risks, doubtful benefit

Sleep Medicine Reviews

Volumn 4, Issue 1, 2000, Pages 5-20

  Kripke, Daniel F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Epidemiology; Flurazepam; Hazard; Hypnotics; Mortality; Triazolam; Zolpidem

Indexed keywords

FLURAZEPAM; HYPNOTIC AGENT; TRIAZOLAM; ZOLPIDEM;

COGNITION; DRUG EFFICACY; DRUG TOLERANCE; DRUG USE; HUMAN; HYPNOSIS; INSOMNIA; LONG TERM CARE; MEMORY; MORTALITY; REVIEW; RISK ASSESSMENT;

EID: 0034113780     PISSN: 10870792     EISSN: None     Source Type: Journal    
DOI: 10.1053/smrv.1999.0076     Document Type: Review

References (83)

1. Wood HC. Functional nervous diseases. Pepper W (ed.). A Text-Book of the Theory and Practice of Medicine by American Teachers. Philadelphia: W.B. Saunders. 1893;661.
2. Kripke DF, Klauber MR, Wingard DL. Mortality hazard associated with prescription hypnotics. Biol Psychiatry. 43:1998;687-693.
3. Woods JH, Katz JL, Winger G. Benzodiazepines: Use, abuse, and consequences. Pharmacological Reviews. 44(2):1992;151-347.
4. Kripke DF. Chronic hypnotic use: the neglected problem. Koella WP, Ruther E, Schulz H (ed.). Sleep '84. Stuttgart: Gustav Fischer Verlag. 1985;338-340.
5. Cooper JR. Sedative-Hypnotic Drugs: Risks and Benefits. Rockville, M.D.: National Institute on Drug Abuse. 1977.
6. Ohayon M, Caulet M, Lemoine P. Sujets âgés, habitudes de sommeil et consommation de psychotropes dans la population française. L'Encéphale. 22:1996;337-350.
7. Hammond EC. Some preliminary findings on physical complaints from a prospective study of 1,064,004 men and women. Am J Public Health. 54:1964;11-24.
8. Kripke DF, Simons RN, Garfinkel L. Short and long sleep and sleeping pills: Is increased mortality associated? Arch Gen Psychiatry. 36:1979;103-116.
9. Foley DJ, Monjan A, Simonsick EM. Incidence and remission of insomnia among elderly adults: An epidemiologic study of 6,800 persons over three years. Sleep. 22(S2):1999;S366-S372.
10. Rumble R, Morgan K. Hypnotics, sleep, and mortality in elderly people. J Am Geriatr Soc. 40:1992;787-791.
11. Allgulander C. History and current status of sedative-hypnotic drug use and abuse. Acta Psychiatrica Scandinavica. 73:1987;465-478.
12. Allgulander C, Nasman B. Regular hypnotic drug treatment in a sample of 32,679 Swedes: associations with somatic and mental health, inpatient psychiatric diagnoses and suicide, derived with automated record-linkage. Psychosom Med. 53(1):1991;101-108.
13. Ungerleider JT, Lundberg GD, Sunshine I. The drug abuse warning network (DAWN) program. Arch Gen Psychiat. 37:1980;106-109.
14. Zorumski CF, Isenberg KE. Insights into the structure and function of GABA-benzodiazepine receptors: ion channels and psychiatry. Am J Psychiatry. 148(2):1991;162-173.
15. Miller NS. Benzodiazepines: behavioral and pharmacologic basis of addiction, tolerance, and dependence. Essent Psychopharmacol. 2:1997;119-145.
16. Robinson RW, Zwillich CW. Drugs and sleep respiration. In Kryger MH, Roth T, Dement WC (eds). Principles and Practice of Sleep Medicine. Second Edition. Philadelphia: W.B. Saunders. 1994;603-620.
17. Guilleminault C. Benzodiazepines, breathing, and sleep. Am J Med. 88:1990;25S-28S.
18. Roth T, Roehrs T, Kryger M. Mortality in Obstructive Sleep Apnea. In Issa FG, Suratt PM, Remmers JE (eds). Sleep and Respiration. New York: Wiley-Liss. 1990;347-352.
19. Strang J, Seivewright N, Farrell M. Intravenous and other novel abuses of benzodiazepines: The opening of Pandora's box? Br J Addiction. 87:1992;1373-1375.
20. Johnson LC, Chernik DA. Sedative-hypnotics and human performance. Psychopharmacology (Berlin). 76:1982;101-113.
21. Morgan K. Hypnotic drugs, psychomotor performance and aging. J Sleep Res. 3:1994;1-15.
22. Bonnet MH, Dexter JR, Gillin JC. The use of triazolam in phase-advanced sleep. Neuropsychopharmacol. 1(3):1988;225-234.
23. Berlin I, Warot D, Hergueta T. Comparison of the effects of zolpidem and triazolam on memory functions, psychomotor performances, and postural sway in healthy subjects. J Clin Psychopharmacol. 13(2):1993;100-106.
24. Wesensten NJ, Balkin TJ, Belenky GL. Effects of daytime administration of zolpidem versus triazolam on memory. J Clin Pharmacol. 48(2):1995;115-122.
25. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med. 319(26):1988;1701-1707.
26. Ray WA, Griffin MR, Schaffner W. Psychotropic drug use and the risk of hip fracture. N Engl J Med. 316:1987;363-369.
27. Campbell AJ, Borrie MJ, Spears GF. Risk factors for falls in a community-based prospective study of people 70 years and older. J Gerontol. 44(4):1989;M112-M117.
28. Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA. 262(23):1989;3303-3307.
29. Ray WA. Psychotropic drugs and injuries among the elderly: A review. J Clin Psychopharmacol. 12(6):1992;386-396.
30. Betts TA, Birtle J. Effect of two hypnotic drugs on actual driving performance next morning. Br Med J. 25 Sept:1982;285-852.
31. Hemmelgarn B, Suissa S, Huang A. Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA. 278(1):1997;27-31.
32. Miller RR, Greenblatt DJ. Hypnotics. In Miller RR, Greenblatt DJ (eds). Drug Effects in Hospitalized Patients. New York: John Wiley & Sons. 1976;171-191.
33. Shapiro S, Stone D, Lewis GP. Clinical effects of hypnotics II. An epidemilogic study. JAMA. 209:1969;2016-2020.
34. Judd LL, Ellinwood E, McAdams LA. Cognitive performance and mood in patients with chronic insomnia during 14-day use of flurazepam and midazolam. J Clin Psychopharmacol. 10:1990;56S-67S.
35. Oswald I, Adam K, Borrow S. The effects of two hypnotics on sleep, subjective feelings, and skilled performance. In Passouant P, Oswald I (eds). Pharmacology of the States of Alertness. Oxford: Pergamon Press. 1979;51-63.
36. Kales A, Soldatos CR, Bixler EO. Rebound insomnia and rebound anxiety: a review. Pharmacology. 26:1983;121-137.
37. Adam K, Oswald AI. Can a rapidly-eliminated hypnotic cause daytime anxiety? Pharmacopsychiat. 22(3):1989;115-119.
38. Kales A, Bixler EO, Tan TL. Chronic hypnotic-drug use: ineffectiveness, drug-withdrawal insomnia, and dependence. JAMA. 227:1974;513-517.
39. Roehrs T, Vogel G, Roth T. Rebound insomnia: Its determinants and significance. Am J Med. 88:1990;39S-42S.
40. Sanchez LGB, Sanchez JM, Moreno JLL. Dependence and tolerance with zolpidem. Am J Health-Syst Pharm. 53:1996;2638-2638.
41. Salzman C, Ellinwood EH, Gillin JC. Benzodiazepine Dependence, Toxicity, and Abuse: A Task Force Report of the American Psychiatric Association. Washington, D.C. American Psychiatric Association. 1990.
42. Miller NS, Gold MS, Stennie K. Benzodiazepines: The dissociation of addiction from pharmacological dependence/withdrawal. Psychiatr Ann. 25(3):1995;149-152.
43. Ashton H. Protracted withdrawal from benzodiazepines: The post-withdrawal syndrome. Psychiatr Ann. 25(3):1995;174-180.
44. Greenblatt DJ, Miller LG, Shader RI. Benzodiazepine discontinuation syndromes. J Psychiatr Res. 24(2):1990;73-79.
45. Scharf MB, Roth T, Vogel GW. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry. 55(5):1994;192-199.
46. Roy-Byrne PP, Cowley DS. Benzodiazepines in Clinical Practice: Risks and Benefits. Washington, D.C.: American Psychiatric Press. 1991.
47. Schneider-Helmert D. Why low-dose benzodiazepine-dependent insomniacs can't escape their sleeping pills. Acta Psychiatrica Scandinavica. 78(6):1988;706-711.
48. Mitler MM, Seidel WF, van den Hoed J. Comparative hypnotic effects of flurazepam, triazolam, and placebo: a long-term simultaneous nighttime and daytime study. J Clin Psychopharmacol. 4:1984;2-15.
49. Johnson LC, Mitler MM, Dement WC. Comparative hypnotic effects of flurazepam, triazolam, and placebo: a reanalysis. Naval Health Research Center Report No. 84-13. Naval Medical Research and Development Command, Bethesda, MD. 1984;1-25.
50. Kripke DF, Hauri P, Ancoli-Israel S. Sleep evaluation in chronic insomniacs during 14-day use of flurazepam and midazolam. J Clin Psychopharmacol. 10(S4):1990;32S-43S.
51. Morin CM, Colecchi C, Stone J. Behavioral and pharmacological therapies for late-life insomnia. JAMA. 281:1999;991-999.
52. Johnson LC, Chernik DA, Hauri P. A multicenter 14-day study of flurazepam and midazolam in chronic insomniacs: general discussion and conclusions. J Clin Psychopharmacol. 10:1990;76S-80S.
53. Morin CM, Bastien CH, Radouco-Thomas M. Late-life insomnia and chronic use of benzodiazepines: medication tapering with and without behavioral intervention. Sleep. 21S:1998;99.
54. Parrino L, Smerieri A, Boselli M. Discontinuation of elevated doses of benzodiazepines used as hypnotics: polysomnographic assessment of sleep parameters. Sleep. 21S:1998;101.
55. Nowell PD, Mazumdar S, Buysse DJ. Benzodiazepines and zolpidem for chronic insomnia: A meta-analysis of treatment efficacy. JAMA. 278:1997;2170-2177.
56. Carskadon MA, Dement WC, Mitler MM. Self-reports versus sleep laboratory findings in 122 drug-free subjects with complaints of chronic insomnia. Am J Psychiatry. 133:1976;1382-1388.
57. Nowell PD, Reynolds CF, Buysse DJ. Paroxetine in the treatment of primary insomnia: preliminary clinical and electroencephalogram sleep data. J Clin Psychiatry. 60:1999;89-95.
58. Roth T, Roehrs T, Linnoila M. Characteristics of chronic insomniacs examined in a multicenter 14-day study of flurazepam and midazolam. J Clin Psychopharmacol. 10:1990;24S-27S.
59. Committee on Halcion, Institute of Medicine. Halcion: An Independent Assessment of Safety and Efficacy Data. Washington, D.C.: National Academy Press. 1997.
60. Gold MS. Rohypnol (flunitrazepam). The Facts About Tobacco, Alcohol and Other Drugs. 4(4):1995;1-2.
61. Hauri PJ. Case Studies In Insomnia. New York: Plenum. 1991.
62. Morin CM, Culbert JP, Schwartz SM. Nonpharmacological interventions for insomnia: A meta-analysis of treatment efficacy. Am J Psychiatry. 151(8):1994;1172-1180.
63. Walsh JK, Schweitzer PK. Ten-year trends in the pharmacological treatment of insomnia. Sleep. 22(3):1999;371-375.
64. National Institute of Medicine. Sleeping Pills, Insomnia, and Medical Practice. Washington, DC: National Academy of Sciences. 1979.
65. Solomon F, White CC, Parron DL. Sleeping pills, insomnia and medical practice. N Engl J Med. 300:1979;803-808.
66. The Pharmaceutical Journal. 1980;384-386.
67. Consensus Conference. Drugs and insomnia. The use of medications to promote sleep. JAMA. 251(18):1984;2410-2414.
68. National Institutes of Health. Consensus development conference statement: the treatment of sleep disorders of older people. Sleep. 14 (2):1991;169-177.
69. Monjan AA. Sleep disorders of older people: report of a consensus conference. Hosp Community Psychiatry. 41(7):1990;743-744.
70. Erman MK, Mendelson WB, Roehrs TA, Roth T, Walsh JK. The Pharmacological Management of Sleep. Washington, D.C.: National Sleep Foundation. 1966.
71. Willis DB, Calle EE, Miracle-McMahill HL. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes and Control. 7:1996;449-457.
72. Jensen E, Dehlin O, Hagberg B. Insomnia in an 80-year-old population: Relationship to medical, psychological and social factors. J Sleep Res. 7:1998;183-189.
73. Huppert FA, Whittington JE. Symptoms of psychological distress predict 7-year mortality. Psychol Med. 25:1995;1073-1086.
74. Ganguli M, Reynolds CF, Gilby JE. Prevalence and persistence of sleep complaints in a rural older community sample: The MoVIES project. J Am Geriatr Soc. 44:1996;778-784.
75. Simon GE, VonKorff M. Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry. 154:1997;1417-1423.
76. Ahmed I, Soares Souza KV, Seifas R. Randomized controlled trials in Archives of General Psychiatry (1959-1995). A prevalence study. Arch Gen Psychiatry. 55:1998;754-755.
77. Wysowski DK, Daum C. Outpatient use of prescription sedative-hypnotic drugs in the United States, 1970 through 1989. Arch Intern Med. 151(9):1991;1779-1783.
78. Kripke DF. U.S. consumption of hypnotics: Do we know? Sleep. 21S:1998;85.
79. Nanterre: Synthelabo. 1997.
80. Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry. 42:1985;225-232.
81. Morgan K, Dallosso H, Ebrahim S. Prevalence, frequency and duration of hypnotic drug use among the elderly living at home. Br Med J. 296:1988;601-602.
82. Ohayon MM, Caulet M. Psychotropic medication and insomnia complaints in two epidemiological studies. Can J Psychia. 41:1996;457-464.
83. Quera-Salva MA, Orluc A, Goldenberg F. Insomnia and use of hypnotics: study of a French population. Sleep. 14(5):1991;386-391.